The annual tick report shows Lone Star ticks have established populations along Connecticut's shoreline, raising the risk of ...
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...
In March 2026, Pfizer and partner Valneva reported that their investigational 6‑valent OspA-based Lyme disease vaccine ...
If approved, the Pfizer-Valneva vaccine could become highly sought-after as Lyme disease surges in the Hudson Valley.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results